Home | Contact Us

Roskamp Institute Patients, Families and Friends Healthcare Professionals Clinical Operations
Roskamp Institute
About Us How to Help News Careers PhD Program Better science. Real discovery.




Role of Anatabine (RCP006 from Rock Creek Pharmaceuticals) as an anti-inflammatory agent

Researchers at the Roskamp Institute are interested in the role of inflammation in aging and in particular in diseases like Alzheimer's Disease. We have shown that specific inflammatory chemicals play a key role in promoting the production of the toxic protein, amyloid, and that this in turn promotes more inflammation. Thus, Alzheimer's Disease is the consequence of a destructive cycle of inflammation where inflammatory chemicals cause the release of each other and cause damage and finally death to neurons in the process.

Inflammation is seen as so central to Alzheimer's Disease, and the aging process in general, that researchers have coined the phrase "inflammaging" to illustrate how entwined aging and inflammation are. Here at the Roskamp Institute researchers are testing drugs and naturally occurring compounds that have anti-inflammatory properties.



Graph above increase in IL-1 release after LPS stimulate stimulation in whole human blood. A dose-dependent decrease in the IL-1 response is shown with increasing levels of anatabine. Lipitor which is thought to have some anti-inflammatory properties is shown by comparison, but has no effect on IL-1 levels at these doses in this assay.

For instance, the graph above shows the effects of increasing doses of anatabine (RCP006 from Rock Creek Pharmaceuticals), a naturally occurring compound, on the release of an inflammatory molecule called interleukin 1-beta (IL-1). The graph shows the release of IL-1 from human blood cells after stimulation with a molecule (LPS) released by bacteria, which typically causes inflammation during infection. The graph shows the expected increase in IL-1 release after this stimulation. However, in the presence of anatabine there is a dose dependent decrease in the release of IL-1. Such results hold promise for the control of inflammation in many human conditions, and research is ongoing at the Roskamp Institute to bring this molecule into clinical studies to test its ability to regulate inflammation.

Top | Home

 

 

 


"We have assembled a fantastic team of scientists and clinicians here at the Roskamp Institute." – Dr. Fiona Crawford